id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-348535-tvs1snq8	Ottaviani, Silvia	What is the best drug to treat COVID-19? The need for randomized controlled trials	2020-05-19		.txt	text/plain	1410	70	48	For example, we have observed 11 that use of baricitinib for 10 days is associated with viral rebound in nasopharyngeal swabs in rapidly recovered and discharged patients, and thus have recommended longer use in the large randomised studies in which it is included, and we suggest again that comparisons between different therapies or placebo are likely to yield more informative results than randomised studies comparing 10 days of intravenous remdesevir with 5 days (https://benevolent.ai/news/potential-treatment-for-covid-19-identified-by-benevolentai-usingartificial-intelligence-enters-clinical-testing And https://investor.lilly.com/news-releases/news-release-details/lilly-begins-clinical-testingtherapies-covid-19). With this in mind, we thoroughly congratulate the authors from Guangzhou, China, who successfully randomised 86 individuals with mild-to-moderate COVID-19 in a 2:2:1 design, to either lopinavir/ritonavir, arbidol (a broad spectrum viral infusion inhibitor 12 ) or placebo (NCT04252885). In the continuing search for safe and effective new therapies to treat patients with COVID-19, we require well-conducted ethical studies including prospective, randomised, placebocontrolled clinical studies such as this.	./cache/cord-348535-tvs1snq8.txt	./txt/cord-348535-tvs1snq8.txt